Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fruquintinib - Hutchison MediPharma

Drug Profile

Fruquintinib - Hutchison MediPharma

Alternative Names: Elunate; HMPL-013

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hutchison MediPharma
  • Developer Eli Lilly and Company; Genor Biopharma; Hutchison MediPharma
  • Class Antineoplastics; Benzofurans; Quinazolines; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase III Gastric cancer; Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 28 Nov 2019 Hutchison MediPharma plans a phase II/III registration study in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in the US and Europe in 2020 (PO, Capsule)
  • 17 Nov 2019 Hutchison Medipharma Limited withdrawn a phase II trial in Non-small cell lung cancer (Late-stage disease) prior enrolment in China due to company's strategy (NCT03684967)
  • 23 Jul 2019 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT03976856)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top